AstraZeneca Pharma India Q4 net profit up nearly 3-fold to Rs 27.27 cr

Drug firm AstraZeneca Pharma India on Tuesday reported a nearly three-fold jump in its net profit to Rs 27.27 crore for the quarter ended March 31, 2021.

AstraZeneca
Press Trust of India New Delhi
1 min read Last Updated : May 25 2021 | 8:14 PM IST

Drug firm AstraZeneca Pharma India on Tuesday reported a nearly three-fold jump in its net profit to Rs 27.27 crore for the quarter ended March 31, 2021.

The company had posted a net profit of Rs 9.57 crore for the corresponding period of the previous fiscal, AstraZeneca Pharma India said in a regulatory filing.

Revenue from operations of the company stood at Rs 210.25 crore for the quarter under consideration. It was Rs 194.90 crore for the same period a year ago, it added.

For the financial year ended March this year, the net profit of the company was Rs 93.30 crore as against Rs 72.22 crore for the previous financial year, the filing said.

The company's revenue from operations stood at Rs 813.56 crore for the financial year ended March 31, 2021. It was Rs 831.80 crore for the year-ago fiscal, it added.

Shares of AstraZeneca Pharma India closed at Rs 3,862.45 per scrip on BSE, up 0.84 percent from its previous close.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :AstraZenecaQ4 Resultscorporate earningsPharma CompaniesCoronavirus VaccineVaccine

First Published: May 25 2021 | 8:04 PM IST

Next Story